亚太地区癫痫市场预测至 2030 年 - 区域分析 - 按类型（渐进性肌阵挛性癫痫、反射性癫痫、全身性癫痫等）、给药途径（口服、肠胃外等）、治疗类型（第一代药物、第二代药物和第三代药物）、年龄组（成人和儿童）和分销渠道（医院药房、零售药房等）
组织开展的宣传计划激增，推动亚太地区癫痫市场发展
人们对癫痫、其症状以及早期诊断重要性的认识不断提高，导致就医患者数量激增。癫痫基金会、癫痫学会、美国癫痫学会和中佛罗里达癫痫协会等组织在教育人们了解这种疾病方面发挥着至关重要的作用。这些组织的参与提高了诊断率，并扩大了需要癫痫治疗的患者群体。世界各地的组织开展了大量宣传活动，以传播有关这种疾病和可用治疗方法的认识。 2023 年，在癫痫紫色日，海得拉巴（印度）的 Aster Prime 医院与 Krishna Kant Park 步行者协会合作举办了一场宣传活动。共有 150 名参与者（包括步行者和瑜伽练习者）参加了此次活动。此外，为了提高患有癫痫的澳大利亚人的生活质量，澳大利亚癫痫行动组织提供了各种工具和服务，旨在提高认识、教育和为个人提供必要的技能。因此，此类举措和宣传活动可增加癫痫诊断和治疗，为市场提供丰厚的增长机会。
亚太癫痫市场概览
亚太癫痫市场基于中国、日本、印度、澳大利亚、韩国和亚太地区其他地区进行分析。根据世界卫生组织 (WHO) 的报告，癫痫在发展中国家比在发达国家更为常见，患病率分别为 6.1% 和 5.0%。
亚太地区癫痫市场收入及预测至 2030 年（百万美元）
亚太地区癫痫市场细分
亚太地区癫痫市场分为类型、给药途径、治疗类型、年龄组、分销渠道和国家。
根据类型，亚太地区癫痫市场分为进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫和其他。全身性癫痫细分市场在 2022 年占据了最大的市场份额。
就给药途径而言，亚太地区癫痫市场分为口服、肠外和其他。口服药物在 2022 年占据了最大的市场份额。
按治疗类型，亚太癫痫市场分为第一代药物、第二代药物和第三代药物。第三代药物在 2022 年占据了最大的市场份额。
根据年龄组，亚太癫痫市场分为成人和儿童。成人部分在 2022 年占据了更大的市场份额。
在分销渠道方面，亚太癫痫市场分为医院药房、零售药房和其他。医院药房部分在 2022 年占据了最大的市场份额。
按国家/地区，亚太癫痫市场分为中国、日本、印度、澳大利亚、韩国和亚太地区其他地区。 2022 年，中国占据了亚太地区癫痫市场的主导份额。
雅培实验室、辉瑞公司、卫材株式会社、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是亚太地区癫痫市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Asia Pacific Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Asia Pacific Analysis
6.1 Asia Pacific: Epilepsy Market
7. Asia Pacific Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Asia Pacific Epilepsy Market - Country Analysis
12.1 Asia Pacific Epilepsy Market Overview
12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 China: Epilepsy Market Overview
12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 Japan: Epilepsy Market Overview
12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 India: Epilepsy Market Overview
12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Australia: Epilepsy Market Overview
12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.9 South Korea: Epilepsy Market Overview
12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
?
List of Tables
Table 1. Asia Pacific Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 41. Recent Organic Growth Strategies in Epilepsy Market
Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market
?
List of Figures
Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 33. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.